#4360dd15
- ABT-263→OSK 间隔的保守锚定原则 20260425183256000
- cell competition is a generic tissue-level quality-control framework 20260425040057000
- senolytic 预处理与 OSK 增效证据未检出 20260425031913000
- 体外与器官类系统中也未检出 senolytic→OSK 原始顺序实验 20260425031655000
- 顺序联合比单药 head-to-head 更有信息量 20260425030652000
- Topical ABT-263 treatment reduces aged skin senescence and improves subsequent wound healing 20260425030358000
- 皮肤 OSK vs ABT-263 参数对齐表（补全版） 20260425030211000
- 皮肤 OSK vs ABT-263 可执行参数表（反证版） 20260425025941000
- 反证式审稿的收敛规则：比较表只能在证据边界内下结论 20260425025750000
- OSK vs ABT-263 的对齐/不对齐清单（皮肤场景） 20260425025615000
- Topical ABT-263 in aged mouse skin: original study and readouts 20260425025523000
- Targeted partial reprogramming of age-associated cell states: skin-relevant OSK parameters 20260425025310000
- 路由匹配的对照实验比“同剂量”更关键 20260425023023000
- OSK vs senolytic direct head-to-head remains sparse across tissues 20260425022737000
- 皮肤中 OSK vs ABT-263 的原始 head-to-head 未检到 20260425022429000
- 同组织头对头证据比并列正例稀缺 20260425021819000
- 统一比较组织的选择原则：皮肤是当前可用候选面板 20260425021710000
- 同一读出面板下比较长寿瓶颈候选的工程准则 20260425021221000
- 第二个长寿瓶颈候选的筛选原则 20260425021002000
- 功能性与组织完整性读出：部分重编程验证的最小并列面板 20260425020502000
- 表观遗传主读出设计原则：组织特异DNAm时钟优先 20260425020313000
- Partial reprogramming 的优先干预模态选择原则 20260425020147000
- 表观遗传信息损失的可检验干预与读出方案 20260425015926000
- 先锁定单一可验证瓶颈，再谈宏大目标 20260425015659000
- Epigenetic information loss as a testable longevity bottleneck 20260425015600000
- 三态判别协议的压力测试结果 20260425015339000
- 旧前缀+下一前缀联合生存刻画中性（small-case） 20260425014335000
- 旧前缀可替代嵌入不足以判别中性 20260425013950000
- 单一局部特征通常只能给出必要条件 20260425013436000
- 单侧交换位置可压缩为局部窗口 20260425010941000
- Iter-4360dd15-0186-fact-left-prefix-consumption-cut 20260425002431000
- Iter-4360dd15-0184-failure-left-split-overclaim 20260424235623000
- Iter-4360dd15-0178-fact-support-contained-window-decidable-audit 20260424234738000
- Iter-4360dd15-0174-fact-exhaustive-reachability-audit 20260424233953000
- Iter-4360dd15-0173-fact-support-contained-boundary-consistency 20260424233814000
- Iter-4360dd15-0172-fact-accept-support-contained-boundary-consistency 20260424233727000
- Iter-4360dd15-0171-fact-minimal-counterexample-support-contained-window 20260424233529000
- Iter-4360dd15-0166-fact-minimal-insertion-reorder-counterexample 20260424232532000
- Iter-4360dd15-0165-method-content-subsequence-local-insertion 20260424232430000
- Iter-4360dd15-0164-lesson-v2-rule-false-positives 20260424232336000
- Iter-4360dd15-0160-method-pmc4083033-rewrite-v2 20260424231537000
- Iter-4360dd15-0159-lesson-rewrite-threshold-failure 20260424231322000
- Iter-4360dd15-0158-method-pmc4083033-sentence-rewrite-template 20260424231132000
- Iter-4360dd15-0157-fact-pmc4083033-word-diff 20260424231031000
- Iter-4360dd15-0156-fact-pmc4083033-xml-offsets 20260424230924000
- Iter-4360dd15-0155-fact-pmc4083033-xml-coordinates 20260424230807000
- Iter-4360dd15-0154-fact-pmc4083033-tokenization-robustness 20260424230648000
- Iter-4360dd15-0153-fact-pmc4083033-direct-xml-diff 20260424230526000
- Iter-4360dd15-0152-fact-pmc4083033-diff-type 20260424230323000
- Iter-4360dd15-0149-lesson-pmc4083033-not-insertion 20260424225824000
- BOLERO-2 erratum abstract verbatim chain 20260424222829000
- BOLERO-2 erratum: full corrected abstract sentence 20260424222041000
- BOLERO-2 erratum: abstract correction scope corroborated from source text 20260424221844000
- BOLERO-2 erratum: exact deleted abstract span 20260424221738000
- BOLERO-2 PMID 22149876 vs PMC4713958: verbatim abstract diff 20260424221644000
- BOLERO-2 erratum: original abstract sentence vs corrected sentence 20260424221539000
- BOLERO-2 erratum verbatim boundary proof 20260424221251000
- BOLERO-2 abstract erratum verbatim comparison 20260424221118000
- BOLERO-2 erratum exact abstract sentence and boundary of correction 20260424221021000
- BOLERO-2 erratum corrected abstract sentence 20260424220843000
- BOLERO-2 abstract should cite erratum-corrected subgroup wording 20260424220656000
- BOLERO-2 erratum scope: subgroup wording only, PFS numerics unchanged 20260424220522000
- BOLERO-2 erratum does not change abstract investigator-assessed PFS sentence or bibliographic metadata 20260424220413000
- BOLERO-2 PMCID and abstract PFS sentence directly verified from PMC 20260424220204000
- BOLERO-2 PMID PMCID DOI confirmed from Europe PMC and PMC 20260424220045000
- BOLERO-2 主文数值与 PMID/DOI 的直接抽取（Springer OA + NCBI export） 20260424215916000
- BOLERO-2 主要终点具体结果数值（Springer OA） 20260424215736000
- BOLERO-2 可访问非-NEJM 设计/终点证据已补齐 20260424215252000
- BOLERO-2 PMID 22149876 的可访问非-NEJM 设计/终点复核 20260424215102000
- BOLERO-2 PMID 22149876 的第二独立复核来源与 primary endpoint 20260424214827000
- BOLERO-2 原始主报告 PMID 22149876 与 primary endpoint PFS 20260424214522000
- PMID 22149876 is the original BOLERO-2 phase 3 primary report, not 24267730 20260424214401000
- PMID 24267730 is a subgroup analysis, not the first original human trial 20260424214147000
- Iter-4360dd15-0106-four-candidate-audit 20260424213752000
- Iter-4360dd15-0104-three-remaining-candidates-are-not-original-first-reports 20260424213638000
- Iter-4360dd15-0103-EuropePMC-38310895-reference-parser-and-candidate-shortlist 20260424213315000
- Iter-4360dd15-0100-human-trial-vs-non-original-screening-of-38310895-references 20260424212530000
- Iter-4360dd15-0099-critic-mechanistic-vs-aging-trial 20260424212312000
- Iter-4360dd15-0098-EuropePMC-extract-human-trial-PMIDs 20260424212055000
- PMID 22367193 is cardiac-repolarization safety, not longevity evidence 20260424210833000
- PMID 24691032 is muscle-protein-synthesis endpoint, not longevity evidence 20260424210355000
- PMID 22115710 is phase I ocular safety study, not longevity evidence 20260424210145000
- PMID 29408453 is feasibility/safety pilot, not direct longevity evidence 20260424210012000
- PMID 31761958 is skin-senescence endpoint, not longevity evidence 20260424205759000
- PMID 33977284 is RTI incidence endpoint, not direct longevity evidence 20260424204839000
- PMID 25540326 is immune-response endpoint, not longevity evidence 20260424204718000
- PMID 27883166 is a pilot safety feasibility trial not direct longevity evidence 20260424204543000
- PEARL trial is not direct longevity evidence 20260424203525000
- Iter-4360dd15-0078-two-pmid-evidence-verification 20260424203242000
- Iter-4360dd15-0077-unified-longevity-classification-four-pmids 20260424203137000
- Iter-4360dd15-0075-abstract-field-extraction-two-pmids 20260424202951000
- Iter-4360dd15-0072-review-exclusion-first-rule 20260424202103000
- Iter-4360dd15-0071-minimal-audit-rules 20260424201843000
- Iter-4360dd15-0069-standardized-audit-table-two-trials 20260424201621000
- Iter-4360dd15-0068-abstract-endpoint-extraction 20260424201407000
- Iter-4360dd15-0067-abstract-endpoints-aging-criteria 20260424201141000
- Iter-4360dd15-0066-TierA-abstracts-and-endpoints-for-aging-criteria 20260424200925000
- Iter-4360dd15-0065-minimal-relevance-decision-rules-for-retained-mtor-trials 20260424200748000
- Iter-4360dd15-0064-relevance-tiering-10-pmids 20260424200602000
- Iter-4360dd15-0063-10-pmid-audit-table 20260424200432000
- Iter-4360dd15-0062-pubmed-title-verification-10-pmids 20260424200328000
- Iter-4360dd15-0061-candidate-audit-10-remaining-pmids 20260424200221000
- PMID 38310895 is a review, not a primary trial 20260424200109000
- PMID 35040506 longitudinal analysis is embedded in primary trial 20260424195939000
- Iter-4360dd15-0058-longevity-evidence-proximity-tagging 20260424195827000
- Iter-4360dd15-0057-study-design-taxonomy-for-retained-trials 20260424195711000
- Iter-4360dd15-0056-pubmed-boundary-confirmation 20260424195548000
- Longitudinal analysis is not an automatic exclusion in trial titles 20260424195414000
- Iter-4360dd15-0053-final-audit-14-candidates 20260424194939000
- Iter-4360dd15-0052-rapamycin-older-cohort-pmid-mapping 20260424194711000
- Iter-4360dd15-0051-secondary-analysis-exclusion-lexicon 20260424194517000
- Iter-4360dd15-0050-candidate-audit-originality-check 20260424194345000
- Iter-4360dd15-0049-crossref-candidate-overgeneration-critique 20260424194224000
- Iter-4360dd15-0048-crossref-trialish-candidate-extraction 20260424194106000
- PMID 38310895 access topology verified 20260424193545000
- Iter-4360dd15-0042-crossref-family-collapse-10-families 20260424192619000
- Iter-4360dd15-0040-crossref-trialish-family-taxonomy 20260424192051000
- Iter-4360dd15-0039-crossref-candidate-family-critique 20260424191812000
- Critique of Crossref trialish filtering for PMID 38310895 reference chain 20260424191745000
- Iter-4360dd15-0038-crossref-human-trial-filter-method 20260424191618000
- Iter-4360dd15-0030-vu-research-portal-entry-without-direct-pdf-link 20260424185400000
- 2024 rapamycin systematic review: abstract-level constraints and what remains missing 20260424175824000
- Added included ADPKD rapalog trial CRAD001ADE12 and its body-weight endpoint 20260424174657000
- Rapamycin human trials: completed studies table from PMC review 20260424174352000
- Iter-4360dd15-0004-critique-rapamycin-evidence 20260424174226000
- Rapamycin human trials: extracted endpoints and outcomes from the 2024 systematic review review pass 1 20260424173529000
- Human longevity interventions evidence maturity matrix 2026-04-25 20260424173237000